Identification of a Novel COL17A1 Compound Heterozygous Mutation in a Chinese Girl with Non-Herlitz Junctional Epidermolysis Bullosa

Abstract

Non-Herlitz junctional epidermolysis bullosa (JEB-nH), an autosomal recessive bullous genodermatosis, is characterized by generalized skin blistering from birth onward, dental anomalies, universal alopecia and nail dystrophy. The underlying defect is mutation of the COL17A1 gene encoding the type XVII collagen, resulting in losing structure for attachment of basal epithelial cells to the matrix. In present study, we described one case of congenitally affected female child aged 10 years, with skin blistering. Dermatologic examination revealed sparse, mild blisters on the face and hand, with profound enamel pitting of the teeth. Skin biopsy from proband’s bullous skin displayed subepidermal bulla formation without acantholysis. The immunofluorescence of anti-type XVII collagen antibody staining showed loss of type XVII collagen staining at the basement membrane zone. A combination of whole exome sequencing (WES) and Sanger sequencing revealed the novel heterozygous mutations (c.4324C>T;p.Q1442* and c.1834G>C;p.G612R) in COL17A1 gene, which could be associated with the observed JEB-nH. One allele had a novel nonsense mutation (c.4324C>T;p.Q1442*), resulting in nonsense-mediated mRNA decay and truncated collagen XVII; the other allele had a novel missense mutation of c.1834G>C;p.G612R in exon 22, causing a glycine-to-arginine substitution in the Gly-X-Y triple helical repeating motifs and decreasing the thermal stability of collagen XVII. Our findings indicate that the genetic test based on WES can be useful in diagnosing JEB-nH patients. The novel pathogenic mutations identified would further expand our understanding of the mutation spectrum of COL17A1 gene in association with the inherited blistering diseases.

Keywords

non-Herlitz junctional epidermolysis bullosa / COL17A1 gene / mutation / whole exome sequencing

References

[1] NakamuraH, SawamuraD, GotoM, et al.. Analysis of the COL17A1 in non-Herlitz junctional epidermolysis bullosa and amelogenesis imperfecta. Int J Mol Med, 2006, 18(2): 333-337

[2] YanceyKB, HintnerH. Non-herlitz junctional epidermolysis bullosa. Dermatol Clin, 2010, 28(1): 67-77

[3] HasC, SpartàG, KiritsiD, et al.. Integrin a3 mutations with kidney, lung, and skin disease. N Engl J Med, 2012, 366(16): 1508-1514

[4] AshtonGH, SorelliP, MellerioJE, et al.. Alpha 6 beta 4 integrin abnormalities in junctional epidermolysis bullosa with pyloric atresia. Br J Dermatol, 2001, 144(2): 408-414

[5] LiH, DurbinR. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics, 2009, 25(14): 1754-1760

[6] LiH, HandsakerB, WysokerA, et al.. The Sequence Alignment/Map format and SAMtools. Bioinformatics, 2009, 25(16): 2078-2079

[7] WangK, LiM, HakonarsonH. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res, 2010, 38(16): e164

[8] NgPC, HenikoffS. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res, 2003, 31(13): 3812-3814

[9] AdzhubeiIA, SchmidtS, PeshkinL, et al.. A method and server for predicting damaging missense mutations. Nat Methods, 2010, 7(4): 248-249

[10] SchwarzJM, RodelspergerC, SchuelkeM, et al.. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods, 2010, 7(8): 575-576

[11] ChunS, FayJC. Identification of deleterious muta-tions within three human genomes. Genome Res, 2009, 19(9): 1553-1561

[12] RevaB, AntipinY, SanderC. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res, 2011, 39(17): e118

[13] YangH, RobinsonPN, WangK. Phenolyzer: phenotype-based prioritization of candidate genes for human diseases. Nat Methods, 2015, 12(9): 841-843

[14] LiQ, WangK. InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. Am J Hum Genet, 2017, 100(2): 267-280

[15] VaisanenL, HasC, FranzkeC, et al.. Molecular mechanisms of junctional epidermolysis bullosa: Col 15 domain mutations decrease the thermal stability of collagen XVII. J Invest Dermatol, 2005, 125(6): 1112-1118

[16] GelseK, PoschlE, AignerT. Collagens—structure, function, and biosynthesis. Adv Drug Deliv Rev, 2003, 55(12): 1531-1546

[17] ShouldersMD, RainesRT. Collagen structure and stability. Annu Rev Biochem, 2009, 78: 929-958

[18] XiaoJ, ChengH, SilvaT, et al.. Osteogenesis imperfecta missense mutations in collagen: structural consequences of a glycine to alanine replacement at a highly charged site. Biochemistry, 2011, 50(50): 10 771-10 780

[19] FloethM, FiedorowiczJ, SchackeH, et al.. Novel homozygous and compound heterozygous COL17A1 mutations associated with junctional epidermolysis bullosa. J Invest Dermatol, 1998, 111(3): 528-533

[20] ShinkumaS. Dystrophic epidermolysis bullosa: a review. Clin Cosmet Investig Dermatol, 2015, 8: 275-284

[21] McGrathJA, GatalicaB, ChristianoAM, et al.. Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmembrane collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa. Nat Genet, 1995, 11(1): 83-86

[22] PasmooijAM, PasHH, JansenGH, et al.. Localized and generalized forms of blistering in junctional epidermolysis bullosa due to COL17A1 mutations in the Netherlands. Br J Dermatol, 2007, 156(5): 861-870

[23] BauerJW, LanschuetzerC. Type XVII collagen gene mutations in junctional epidermolysis bullosa and prospects for gene therapy. Clin Exp Dermatol, 2003, 28(1): 53-60

[24] Bruckner-TudermanL, HasC. Molecular Heterogeneity of Blistering Disorders: The Paradigm of Epidermolysis Bullosa. J Invest Dermatol, 2012, 132(Suppl 3): E2-5

[25] LuckyAW, DagaonkarN, LammersK, et al.. A comprehensive next-generation sequencing assay for the diagnosis of epidermolysis bullosa. Pediatr Dermatol, 2018, 35(2): 188-197

[26] TakeichiT, LiuL, FongK, et al.. Whole-exome sequencing improves mutation detection in a diagnostic epidermolysis bullosa laboratory. Br J Dermatol, 2015, 172(1): 94-100

[27] MeienbergJ, BruggmannR, OexleK, et al.. Clinical sequencing: is WGS the better WES?. Hum Genet, 2016, 135(3): 359-362